These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24259278)

  • 1. Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells.
    Hart NJ; Chung WJ; Weber C; Ananthakrishnan K; Anderson M; Patek R; Zhang Z; Limesand SW; Vagner J; Lynch RM
    Chembiochem; 2014 Jan; 15(1):135-45. PubMed ID: 24259278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivalent activation of GLP-1 and sulfonylurea receptors modulates β-cell second-messenger signaling and insulin secretion.
    Hart NJ; Weber C; Papas KK; Limesand SW; Vagner J; Lynch RM
    Am J Physiol Cell Physiol; 2019 Jan; 316(1):C48-C56. PubMed ID: 30404557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Synthetic Heterobivalent Ligand Composed of Glucagon-Like Peptide 1 and Yohimbine Specifically Targets β Cells Within the Pancreas.
    Steyn LV; Ananthakrishnan K; Anderson MJ; Patek R; Kelly A; Vagner J; Lynch RM; Limesand SW
    Mol Imaging Biol; 2015 Aug; 17(4):461-70. PubMed ID: 25604385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor.
    Underwood CR; Garibay P; Knudsen LB; Hastrup S; Peters GH; Rudolph R; Reedtz-Runge S
    J Biol Chem; 2010 Jan; 285(1):723-30. PubMed ID: 19861722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells.
    Sonoda N; Imamura T; Yoshizaki T; Babendure JL; Lu JC; Olefsky JM
    Proc Natl Acad Sci U S A; 2008 May; 105(18):6614-9. PubMed ID: 18445652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
    Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
    Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation.
    Estall JL; Koehler JA; Yusta B; Drucker DJ
    J Biol Chem; 2005 Jun; 280(23):22124-34. PubMed ID: 15817468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of PPARβ/δ protects pancreatic β cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor.
    Yang Y; Tong Y; Gong M; Lu Y; Wang C; Zhou M; Yang Q; Mao T; Tong N
    Cell Signal; 2014 Feb; 26(2):268-78. PubMed ID: 24269940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB.
    Cunha DA; Ladrière L; Ortis F; Igoillo-Esteve M; Gurzov EN; Lupi R; Marchetti P; Eizirik DL; Cnop M
    Diabetes; 2009 Dec; 58(12):2851-62. PubMed ID: 19720788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.
    Zhang L; Navaratna T; Liao J; Thurber GM
    Bioconjug Chem; 2015 Feb; 26(2):329-37. PubMed ID: 25594741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand binding pocket formed by evolutionarily conserved residues in the glucagon-like peptide-1 (GLP-1) receptor core domain.
    Moon MJ; Lee YN; Park S; Reyes-Alcaraz A; Hwang JI; Millar RP; Choe H; Seong JY
    J Biol Chem; 2015 Feb; 290(9):5696-706. PubMed ID: 25561730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case study.
    Riz M; Pedersen MG; Toffolo GM; Haschke G; Schneider HC; Klabunde T; Margerie D; Cobelli C
    Am J Physiol Endocrinol Metab; 2014 Mar; 306(6):E627-34. PubMed ID: 24425760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.
    Runge S; Schimmer S; Oschmann J; Schiødt CB; Knudsen SM; Jeppesen CB; Madsen K; Lau J; Thøgersen H; Rudolph R
    Biochemistry; 2007 May; 46(19):5830-40. PubMed ID: 17444618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation.
    Schelshorn D; Joly F; Mutel S; Hampe C; Breton B; Mutel V; Lütjens R
    Mol Pharmacol; 2012 Mar; 81(3):309-18. PubMed ID: 22108912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.
    Koole C; Wootten D; Simms J; Miller LJ; Christopoulos A; Sexton PM
    J Biol Chem; 2012 Feb; 287(6):3642-58. PubMed ID: 22147710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
    Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
    J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potent α/β-peptide analogue of GLP-1 with prolonged action in vivo.
    Johnson LM; Barrick S; Hager MV; McFedries A; Homan EA; Rabaglia ME; Keller MP; Attie AD; Saghatelian A; Bisello A; Gellman SH
    J Am Chem Soc; 2014 Sep; 136(37):12848-51. PubMed ID: 25191938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism.
    Light PE; Manning Fox JE; Riedel MJ; Wheeler MB
    Mol Endocrinol; 2002 Sep; 16(9):2135-44. PubMed ID: 12198249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.